Effectiveness and Adverse Events of Use of Natalizumab in a Brazilian Cohort of Patients With Multiple Sclerosis
Author:
Publisher
Elsevier BV
Subject
Pharmacology (medical),Pharmacology
Reference33 articles.
1. Brain health: time matters in multiple sclerosis;Giovannoni;Mult Scler Relat Disord,2016
2. Principles of a new treatment algorithm in multiple sclerosis;Hartung;Expert Rev Neurother,2011
3. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study;Gajofatto;Eur Neurol,2014
4. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study;Sangalli;Neurol Sci,2011
5. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis;Polman;N Engl J Med,2006
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Esclerose múltipla no Brasil: uma revisão sistemática dos anos de 2010-2023;Journal Archives of Health;2024-07-22
2. Ethnic disparities in the epidemiological and clinical characteristics of multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-01
3. Do magnetic resonance imaging features differ between persons with multiple sclerosis of various races and ethnicities?;Frontiers in Neurology;2023-06-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3